Correction: Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs

Correction to: International Journal of Clinical Oncology

10.1007/s10147-026-03083-2

In Table 2 of this article, the values under the column header ‘PFS (Cox hazard analysis)’ were inadvertently omitted. For completeness and transparency, the old incorrect version and the corrected version of Table 2 are displayed below.

Table 2.

Identification of factors associated with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)

	ORR (Logistic regression analysis)			PFS (Cox hazard analysis)			OS (Cox hazard analysis)
	OR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Univariate analysis
Age, years	1.014	0.964–1.064	0.586	0.993	0.971–1.017	0.569	1.005	0.976–1.037	0.769
Sex, male	0.889	0.268–3.065	0.848	0.902	0.521–1.559	0.711	0.926	0.460–1.866	0.830
Smoking history, current or former	0.889	0.268–3.065	0.848	0.845	0.487–1.467	0.550	0.903	0.448–1.820	0.775
BMI	0.996	0.836–1.198	0.969	0.999	0.920–1.080	0.982	1.031	0.931–1.135	0.540
ECOG PS, ≥ 2	0.104	0.013–0.607	0.012*	2.330	0.980–5.542	0.056	4.716	1.906–11.667	< 0.001***
Stage, III or recurrence	NA†	NA†	0.316	0.469	0.065–3.406	0.455	0.781	0.107–5.724	0.808
Histological type, adeno	NA†	NA†	0.480	0.866	0.118–6.326	0.887	NA††	NA††	0.999
EGFR mutation
Exon 19 deletion	ref			ref			ref
L858R mutation	0.333	0.079–1.222	0.098	0.997	0.560–1.777	0.993	1.293	0.607–2.753	0.506
Uncommon mutation	0.370	0.054–3.177	0.335	1.320	0.542–3.215	0.541	3.721	1.405–9.851	0.008**
Baseline tumor metastasis
Brain metastasis, +	1.103	0.329–4.045	0.876	1.490	0.858–2.586	0.157	0.941	0.468–1.893	0.866
Pleural effusion, +	0.370	0.101–1.233	0.106	1.323	0.769–2.276	0.312	2.579	1.278–5.201	0.008**
Liver metastasis, +	0.805	0.199–4.080	0.774	1.146	0.588–2.234	0.690	2.008	0.926–4.352	0.077
EGFR-TKI generation
First-generation	0.889	0.208–3.390	0.865	1.573	0.859–2.882	0.143	0.918	0.430–1.962	0.826
Second-generation	0.296	0.044–1.978	0.202	1.686	0.658–4.323	0.277	1.485	0.515–4.279	0.464
Third-generation	ref			ref			ref
Serum tVEGF-A, per 100 pg/mL	0.915	0.800–1.021	0.110	1.035	0.984–1.078	0.132	1.053	0.986–1.108	0.079
Serum VEGF121, per 100 pg/mL	0.818	0.661–0.962	0.015*	1.110	1.027–1.187	0.004**	1.052	0.963–1.126	0.199
Serum VEGF165, per 100 pg/mL	0.762	0.505–1.036	0.083	1.090	0.948–1.216	0.172	1.155	0.953–1.335	0.089
Multivariate analysis
Age, years	1.009	0.938–1.085	0.811	1.000	0.974–1.028	0.977	1.028	0.992–1.068	0.147
Sex, male	1.465	0.320–6.713	0.623	0.702	0.371–1.327	0.276	0.741	0.340–1.611	0.449
ECOG PS, ≥ 2	0.056	0.004–0.722	0.027*	1.323	0.483–3.621	0.586	6.604	2.013–21.661	0.002**
EGFR mutation
Exon 19 deletion	ref			ref			ref
L858R mutation	0.130	0.019–0.864	0.035*	1.013	0.519–1.978	0.970	1.648	0.666–4.075	0.280
Uncommon mutation	0.315	0.031–3.247	0.332	1.838	0.703–4.809	0.215	6.068	1.953–18.849	0.002**
Baseline tumor metastasis
Brain metastasis, +	2.209	0.383–12.731	0.489	1.080	0.564–2.069	0.817	0.710	0.278–1.814	0.475
EGFR-TKI generation
First-generation	1.081	0.196–5.956	0.929	2.070	1.060–4.045	0.033*	1.007	0.418–2.427	0.988
Second-generation	0.317	0.021–4.866	0.410	2.237	0.781–6.406	0.134	2.421	0.686–8.541	0.169
Third-generation	ref			ref			ref
Serum VEGF121, per 100 pg/mL	0.786	0.582–0.972	0.025*	1.149	1.050–1.248	0.001**	1.090	0.979–1.200	0.092

^*p < 0.05, ^**p < 0.01, and ^***p < 0.001, logistic regression analysis or Cox proportional hazard model

^†OR and 95% CI could not be calculated because only one group responded to EGFR-TKI

^††HR and 95% CI could not be calculated because no event occurred in one group

Incorrect Table 2:

Table 2.

Identification of factors associated with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)

	ORR Logistic regression analysis)			OS (Cox hazard analysis)
	OR	95% CI	p-value	HR	95% CI	p-value
Univariate analysis
Age, years	1.014	0.964–1.064	0.586	1.005	0.976–1.037	0.769
Sex, male	0.889	0.268–3.065	0.848	0.926	0.460–1.866	0.830
Smoking history, current or former	0.889	0.268–3.065	0.848	0.903	0.448–1.820	0.775
BMI	0.996	0.836–1.198	0.969	1.031	0.931–1.135	0.540
ECOG PS, ≥ 2	0.104	0.013–0.607	0.012*	4.716	1.906–11.667	<0.001***
Stage, III or recurrence	NA†	NA†	0.316	0.781	0.107–5.724	0.808
Histological type, adeno	NA†	NA†	0.480	NA††	NA†	0.999
EGFR mutation
Exon 19 deletion	ref	ref
L858R mutation	0.333	0.079–1.222	0.098	1.293	0.607–2.753	0.506
Uncommon mutation	0.370	0.054–3.177	0.335	3.721	1.405–9.851	0.008**
Baseline tumor metastasis
Brain metastasis, +	1.103	0.329–4.045	0.876	0.941	0.468–1.893	0.866
Pleural effusion, +	0.370	0.101–1.233	0.106	2.579	1.278–5.201	0.008**
Liver metastasis, +	0.805	0.199–4.080	0.774	2.008	0.926–4.352	0.077
EGFR-TKI generation
First-generation	0.889	0.208–3.390	0.865	0.918	0.430–1.962	0.826
Second-generation	0.296	0.044–1.978	0.202	1.485	0.515–4.279	0.464
Third-generation	ref	ref
Serum tVEGF-A, per 100 pg/mL	0.915	0.800–1.021	0.110	1.053	0.986–1.108	0.079
Serum VEGF121, per 100 pg/mL	0.818	0.661–0.962	0.015*	1.052	0.963–1.126	0.199
Serum VEGF165, per 100 pg/mL	0.762	0.505–1.036	0.083	1.155	0.953–1.335	0.089
Multivariate analysis
Age, years	1.009	0.938–1.085	0.811	1.028	0.992–1.068	0.147
Sex, male	1.465	0.320–6.713	0.623	0.741	0.340–1.611	0.449
ECOG PS, ≥ 2	0.056	0.004–0.722	0.027*	6.604	2.013–21.661	0.002**
EGFR mutation
Exon 19 deletion	ref	ref
L858R mutation	0.130	0.019–0.864	0.035*	1.648	0.666–4.075	0.280
Uncommon mutation	0.315	0.031–3.247	0.332	6.068	1.953–18.849	0.002**
Baseline tumor metastasis
Brain metastasis, +	2.209	0.383–12.731	0.489	0.710	0.278–1.814	0.475
EGFR-TKI generation
First-generation	1.081	0.196–5.956	0.929	1.007	0.418–2.427	0.988
Second-generation	0.317	0.021–4.866	0.410	2.421	0.686–8.541	0.169
Third-generation	ref	ref
Serum VEGF121, per 100 pg/mL	0.786	0.582–0.972	0.025*	1.090	0.979–1.200	0.092

^*p < 0.05, ^**p < 0.01, and ^***p < 0.001, logistic regression analysis or Cox proportional hazard model

^†OR and 95% CI could not be calculated because only one group responded to EGFR-TKI

^††HR and 95% CI could not be calculated because no event occurred in one group

Correct Table 2:

The original article has been corrected.